Meeting
2020 Genitourinary Cancers Symposium
Prognostic significance of rate of tumor marker (TM) decline during high-dose chemotherapy (HDCT) for relapsed germ cell tumors (rGCT).
Authors
Nabil Adra
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
Nabil Adra , Sandra K. Althouse , Rafat Abonour , Mohammad Issam Abu Zaid , Hao Liu , Nasser H. Hanna , Lawrence Einhorn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 403)
Abstract #
403
Poster Bd #
E2
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Phase 2 trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) for refractory germ-cell tumors (GCT).
First Author: Yago Nieto
Poster
2024 ASCO Annual Meeting
High dose chemotherapy in male patients with germ cell cancer: A population-based study by the SWENOTECA group.
First Author: Anna Jansson
Poster
2022 ASCO Annual Meeting
Salvage high-dose chemotherapy (HDCT) for relapsed primary mediastinal nonseminomatous germ-cell tumors (PMNSGCT).
First Author: Fadi Taza
Poster
2022 ASCO Annual Meeting
Impact of induction approach on post-stem cell transplant (SCT) outcomes in older adults with newly diagnosed acute myeloid leukemia (AML).
First Author: Faustine Ong